35results about "Microbiology" patented technology

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

The invention discloses a skeletal muscle repair method and system based on muscle satellite cell regulation and control. The method comprises the following steps: performing proliferation and differentiation correlation analysis on satellite cell steady state data and aerobic exercise intensity data to establish a proliferation regulation and control map; determining a collaborative repair time window according to the atlas, extracting difference response deviation correction parameters to form an activity correction factor, and performing repair intensity correction on the collaborative repair time window to generate a self-adaptive repair window; carrying out exercise prescription adaptation on the self-adaptive repair window, identifying a satellite cell activation regulation and control channel, obtaining activation delay time through activation efficiency mapping, and delimiting a response level according to the activation delay time to generate layered repair configuration; activation delay evaluation is conducted on layered repair configuration to determine a preferred activation mode, dynamic activation characteristics are extracted based on optimal activation time window data to form an intervention execution sequence, a skeletal muscle repair execution instruction is output in combination with an exercise prescription parameter table, and dynamic collaborative adaptation of satellite cell repair state monitoring and training scheme parameters is achieved.

The disclosure relates to methods for treating cancer or selecting subjects for cancer treatment using low PD-L1 expression as a patient biomarker prior to treatment.

Disclosed herein are biomarkers that correlate with responses to an anti-ILT4 and anti-PD-1 combination therapy. A biomarker that can differentiate responders from non-responders to this combination therapy can potentially be used to select human subjects who have a higher probability to benefit from such a combination therapy. In one embodiment, a combined positive score (CPS) for PD-L1 expression in a tumor sample from a human subject is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy. In another embodiment, a T-cell–inflamed gene expression profile (TcellinfGEP) score is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy.

Disclosed are methods of treating of a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells, wherein the subject has an isocitrate dehydrogenase mutation (IDHmut). Disclosed are methods of treating a subject comprising identifying a subject with an IDHmut; and applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells.

The present invention relates to methods and systems for detecting one or more analytes in a sample and / or for classifying a sample. In particular, the present invention relates to methods and systems which can be used to detect the analytes in real time and which rely on flowing through a microfluidic device one or more types of sensor molecule each comprising a domain that binds one or more analytes, a chemiluminescent donor domain and an acceptor domain, wherein the separation and relative orientation of the chemiluminescent donor domain and the acceptor domain, in the presence and / or absence of analyte is within ± 50% of the Forster distance.

The invention provides a marker, a kit containing the marker, application of the marker and a use method of the marker. The marker comprises at least one selected from the group consisting of MUC1, MUC5AC, and Claudin18.2. The invention also relates to a method for preparing the marker. The marker and the kit containing the marker can be used for predicting prognosis of the intrahepatic cholangiocarcinoma, predicting the curative effect of targeted therapy and postoperative adjuvant therapy on the intrahepatic cholangiocarcinoma based on tumor expression states, and performing classified prediction on a big bile duct type and a small bile duct type of the intrahepatic cholangiocarcinoma. The disclosure also provides a method of cancer prognosis comprising detecting the expression of the marker and predicting the degree of benefit from post-operative adjuvant therapy in a subject, and / or the prognosis of cancer, particularly intrahepatic cholangiocarcinoma, in a subject. The present disclosure provides universal markers that can be used to predict the efficacy of postoperative adjuvant therapy, such as postoperative adjuvant chemotherapy, on intrahepatic cholangiocarcinoma.

The application discloses an antibody (YHWG-1) against HLA-G molecules and application, the antibody (YHWG-1) is produced by hybridoma with the preservation number of CCTCC NO:202120, using all currently known 7 HLA-G isomer molecules (HLA-G1, HLA-G2, HLA-G3, HLA-G4, HLA-G5, HLA-G6 and HLA-G7) shared, the antigen peptide (QTDRMNLQTLRGYYNQSEAS) of the 72~91 amino acid sequence in the HLA-G molecule heavy chain alpha 1 domain is immunogen.The application provides nucleotide and the amino acid sequence coded by the YHWG-1 antibody of the application, and the application also provides the application of the YHWG-1 antibody for HLA-G isomer molecule immunohistochemical, immunoblotting and flow cytometry detection.

Disclosed are methods of treating of a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells, wherein the subject has an isocitrate dehydrogenase mutation (IDHmut). Disclosed are methods of treating a subject comprising identifying a subject with an IDHmut; and applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells.

The invention provides an anti-human CXCL13 rabbit monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of immune globulin, the anti-human CXCL13 rabbit monoclonal antibody can be specifically combined with CXCL13 protein, the specificity and sensitivity of immunodetection are remarkably improved, the anti-human CXCL13 rabbit monoclonal antibody is suitable for preparing an immunohistochemical detection kit, and the anti-human CXCL13 rabbit monoclonal antibody can be used for preparing immunohistochemical detection products. CXCL13 protein expression can be accurately detected, and a reliable tool is provided for diagnosis of diseases such as vascular immune maternal T cell lymphoma and peripheral T cell lymphoma.

Aspects of the present disclosure are directed to survivin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such survivin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using survivin-targeting polypeptides.

The invention provides methods and compositions for accurate identification and determination of Parkinson's disease ante-mortem tissue samples. The determination of Parkinson's disease is based on the binding of localized phosphorylated alpha-synuclein with the nerve feature. The methods disclosed in the invention may be used on myriad tissue types and could be manual or automated.

Endonuclease V Immunostaining Assay (EndoVIA) is provided herein as the first approach for quantifying and visualizing the landscape of Adenosine-to-Inosine (A-to-I) edited RNAs in situ. EndoVIA provides rapid quantification of overall inosine abundance and allows cell-to-cell comparison of A-to-I editing levels without the need for RNA sequencing. EndoVIA contributes valuable new insights into the dynamic interplay between A-to-I editing and subcellular localization that are undetectable with currently available approaches.

This invention provides an anti-human CXCL13 rabbit monoclonal antibody, its preparation method, and its application, belonging to the field of immunoglobulin technology. This invention provides an anti-human CXCL13 rabbit monoclonal antibody that can specifically bind to the CXCL13 protein, significantly improving the specificity and sensitivity of immunoassay. It is suitable for preparing immunohistochemical detection kits and can accurately detect CXCL13 protein expression, providing a reliable tool for the diagnosis of diseases such as angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

Endonuclease V Immunostaining Assay (EndoVIA) is provided herein as the first approach for quantifying and visualizing the landscape of Adenosine-to-Inosine (A-to-I) edited RNAs in situ. EndoVIA provides rapid quantification of overall inosine abundance and allows cell-to-cell comparison of A-to-I editing levels without the need for RNA sequencing. EndoVIA contributes valuable new insights into the dynamic interplay between A-to-I editing and subcellular localization that are undetectable with currently available approaches.

Disclosed are scoring functions for predicting the response of dMMR and / or MSI-H colorectal tumors to PD-1 axis-directed therapy, as well as methods and systems for evaluating tissue samples for the presence of feature metrics useful for calculating such scoring functions. The scoring function integrates one or more spatial relationships between cell types into a numerical representation of the likelihood that the tumor will respond to PD-1 axis-directed therapy. Then, based on the output of the scoring function, the subject can be selected to receive PD-1 axis-directed therapy (if the scoring function indicates a sufficient likelihood of positive response) or alternative therapy (if the scoring function indicates an insufficient likelihood of positive response).

A method of imaging a biological sample is disclosed, which comprises coupling at least one affinity probe to the biological sample, wherein the affinity probe includes a cleavable tag, bringing the probe-coupled biological sample into contact with a non-selective capture surface so as to couple said at least one cleavable tag to the capture surface, subsequently, cleaving the at least one tag from the affinity probe so as to transfer the at least one tag to the capture surface, thereby generating a replica of the biological sample.

The invention relates to a method for multiplex staining of a biological sample involving the use of a buffer combination of blocking buffer, imaging buffer and elution buffer that allows for multiple staining rounds of biological samples. The blocking buffer comprises a compound that is capable of binding to hydrophobic binding sites non-specifically and a sulfhydryl-reactive compound. The imaging buffer is at neutral pH and comprises a radical scavenger, and the elution buffer is at pH lower than 4 and comprises a buffering component, a reducing agent and at least one compound disrupting hydrogen bonds. The invention further relates to buffers used in the practice of the method of the invention, and to a kit containing these buffers.

The application discloses a rat benign prostatic hyperplasia model, a building method and application thereof, and belongs to the technical field of animal models. The building method comprises the following steps: D-galactose and testosterone undecanoate are jointly administered to rats in adaptive feeding to induce benign prostatic hyperplasia; the induction time is 60 days, D-galactose with a dosage of 125mg / kg / d-500mg / kg / d is continuously given to the rats by subcutaneous injection within 60 days, and testosterone undecanoate olive oil solution with a dosage of 15mg / kg / 10d is given to the rats by intraperitoneal injection starting from the 30th day. The prostate index of the rat benign prostatic hyperplasia model induced by D-galactose and testosterone undecanoate, serum hormone levels, histopathology, androgen receptor and proliferation-related molecules and testicular function are detected to comprehensively evaluate the effectiveness and practicability of the model, and the results show that the rat prostatic hyperplasia model induced by aging and androgen in the application is more close to the pathogenic characteristics of clinical benign prostatic hyperplasia.

The subject matter described herein provides methods for treating an autoimmune disease in a subject, comprising administering to the subject an effective amount of a conjugate that comprises an IGF-1R ligand, or portion or variant thereof, and a disease-modifying agent.

A method and apparatus for labeling a tissue section is provided. In certain aspects, the methods comprise labeling a tissue sample via a plurality of immunohistochemistry (IHC) assays for detection of markers for characterization of a cancer origin in an individual having a cancer of unknown primary (CUP). The disclosed IHC assays employ chromogen-based detection methods for improved sample efficiency and visualization of biomarkers. Further disclosed is an apparatus for carrying out the disclosed methods.

Here provided an antibody YWHG-1 against HLA-G molecule and use thereof. The antibody is produced by the hybridoma deposited under CCTCC NO: 202120, and is prepared by an immunogen with amino acids which are common to seven known HLA-G isoforms (HLA-G1, HLA-G2, HLA-G3, HLA-G4, HLA-G5, HLA-G6 and HLA-G7) which is located at positions 72-91 (QTDRMNLQTLRGYYNQSEAS) in the heavy chain α1 domain of the HLA-G molecule. The present invention provides nucleotides encoding the antibody YWHG-1 and encoded amino acid sequences thereof. The antibody YWHG-1 can be used for immunohistochemistry, immunoblotting, flow cytometry and other assays for HLA-G isoforms.

In alternative embodiments, provided are immunohistochemistry (IHC) methods and kits for determining and scoring reproducibly the extent of expression of the protein tyrosine-protein kinase-like 7 (PTK7), also known as: colon carcinoma kinase 4 (CCK4); HER2 or receptor tyrosine-protein kinase erbB-2, or cluster of differentiation 340 (CD340); programmed death-ligand 1 (PD-L1), or cluster of differentiation 274 (CD274); B7 homolog 1 (B7-H1); and, Ki-67 or MKI67 (Marker of Proliferation Ki-67), in a tissue sample. In alternative embodiments, provided are methods and kits for diagnosing or selecting an individual eligible for treatment with a cancer or tumor therapeutic, or assessing the risk of recurrence for a cancer or a tumor using an IHC method as provided herein. In alternative embodiments, provided are kits comprising components and instructions for practicing methods as provided herein. The present application describes methods for scoring PTK7 expression and utilizing the score as a companion or complementary diagnostic, or to aid the treatment or amelioration of a cancer or a tumor.

Disclosed are methods for generating enhanced multiplex images. The methods may comprise a blank image for each set of markers prior to imaging the markers and subtracting out the blank image intensity from the acquired image of interest. The methods may further comprise acquiring a pre-run blank of the sample prior to collecting an image of interest.

The present disclosure is directed to a triplex immunohistochemical assay for detecting the colocalization of the ER, PR, and Ki-67 biomarkers in cells or cell nuclei. It is believed that the brightfield triplex immunohistochemical assay of the present disclosure may serve as a prognostic assay for ER-positive breast cancer, facilitating the identification of disease-free survivors among ER-positive breast cancer patients treated with hormone therapy.

Methods of treating solid tumors, such as squamous cancer (such as head and neck squamous cell carcinoma), ER- PR- HER2 / neu- ("triple-negative") breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, and gynecological malignancy, in subjects are described. The methods may comprise administering an anti-FGFR2b antibody to the subject.

The present disclosure is directed to a triplex immunohistochemical assay for detecting the colocalization of the ER, PR, and Ki-67 biomarkers in cells or cell nuclei. It is believed that the brightfield triplex immunohistochemical assay of the present disclosure may serve as a prognostic assay for ER-positive breast cancer, facilitating the identification of disease-free survivors among ER-positive breast cancer patients treated with hormone therapy.

The invention discloses application of D74 as a biomarker in preparation of a kit for evaluating or diagnosing bullous pemphigus. The CD74 expression of the skin lesion part of a to-be-detected subject and the CD74 expression of the corresponding position of the normal skin are compared, bullous pemphigus is positive if the CD74 at the skin lesion part is linearly deposited along the true epidermis junction, and the normal tissue is not positively stained. A BP characteristic gene module is identified by adopting a multi-omics integration analysis strategy, and it is found that the CD74 expression level is remarkably related to the eosinophilic granulocyte infiltration degree; the potential of the aptamer as a diagnostic biomarker is verified in patient tissues through immunohistochemistry, the detection sensitivity is 100%, the specificity is 83.3%, the positive predictive value is 78.9%, and the accuracy is 89.7%.

Methods are described for treating solid tumors in a subject, such as squamous cell carcinoma (such as head and neck squamous cell carcinoma), ER-PR-HER2 / neu- ("triple negative") breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, and gynecological malignancies. The methods may include administering to the subject an anti-FGFR2b antibody.